Business
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Pharma and life science companies strengthen their leadership teams and boards of directors with this week’s appointments.
Bio Buzz selected five women venture capitalists who are considered “trailblazing investors shaping the future of life science investing” in the BioCapital Hotbed Community, which includes Delaware, Maryland, Virginia and Washington, D.C.
The government said Petit and former Chief Operating Officer William Taylor engaged in a scheme to “fraudulently inflate” the revenue of MiMedx.
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced that the company will participate in the following upcoming investor conferences in December
Mesoblast Limited reported operational highlights and financial results for the first quarter ended September 30, 2019.
Teewinot Life Sciences Corporation announced Michael Luther Ph.D., Chief Executive Officer, will participate on the Future of Cannabinoid Biosynthesis Panel at the 31st Annual Piper Jaffray Healthcare Conference in New York being held from December 3rd – 5th, 2019 at the Lotte New York Palace.
Medexus Pharmaceuticals Inc. announced that it plans to host a conference call at 8:00 AM Eastern Time on Monday, December 2, 2019 to discuss the Company’s financial results for the second quarter ended September 30, 2019, as well as the Company’s corporate progress and other developments.
Patented AltuCaps® for Microencapsulation of stem cells for autoimmune and inflammatory diseases: Partnering opportunities available
Dr. Singh is renowned for her expertise in molecular science, clinical management and national health policy
La Jolla Pharmaceutical Company, a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, announced that George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, has left the Company to pursue other interests.